MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

SpringWorks Therapeutics Inc

Open

SectorGezondheidszorg

44.42 7.79

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

41.07

Max

46.21

Belangrijke statistieken

By Trading Economics

Inkomsten

-24M

-77M

Verkoop

12M

62M

EPS

-1.04

Winstmarge

-125.586

Werknemers

368

EBITDA

-23M

-80M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+75.93% upside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1B

3.1B

Vorige openingsprijs

36.63

Vorige sluitingsprijs

44.42

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

SpringWorks Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 feb 2025, 07:03 UTC

Acquisities, Fusies, Overnames

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10 feb 2025, 16:38 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

24 apr 2025, 22:51 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into

24 apr 2025, 20:50 UTC

Acquisities, Fusies, Overnames

Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ

24 apr 2025, 19:05 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ

24 apr 2025, 19:05 UTC

Acquisities, Fusies, Overnames

Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ

11 feb 2025, 10:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11 feb 2025, 10:52 UTC

Marktinformatie
Acquisities, Fusies, Overnames

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Peer Vergelijking

Prijswijziging

SpringWorks Therapeutics Inc Prognose

Koersdoel

By TipRanks

75.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 72.5 USD  75.93%

Hoogste 84 USD

Laagste 63 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor SpringWorks Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Technische score

By Trading Central

37.9899 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.